EMEA-002559-PIP04-21
Key facts
Active substance |
Anti-neonatal Fc receptor human monoclonal antibody
|
Therapeutic area |
Neurology
|
Decision number |
P/0419/2021
|
PIP number |
EMEA-002559-PIP04-21
|
Pharmaceutical form(s) |
Solution for infusion
|
Condition(s) / indication(s) |
Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Janssen-Cilag International NV
E-mail: contact@janssen-emea.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|